Decreased catalytic function with altered sumoylation of DNA topoisomerase I in the nuclei of scleroderma fibroblasts

IntroductionSumoylation is involved in nucleolus-nucleoplasm transport of DNA topoisomerase I (topo I), which may associate with changes of cellular and topo I functions. Skin fibroblasts of patients with systemic sclerosis (SSc) exhibit profibrotic cellular changes. The aims of this study were to examine the catalytic function and sumoylation of topo I in the nuclei of SSc fibroblasts, a major cell type involved in the fibrotic process.MethodsEleven pairs of fibroblast strains obtained from nonlesional skin biopsies of SSc patients and age/sex/ethnicity-matched normal controls were examined for catalytic function of nuclear topo I. Immunoprecipitation (IP)-Western blots were used to examine sumoylation of fibroblast topo I. Real-time quantitative RT-PCR was used to measure transcript levels of SUMO1 and COL1A2 in the fibroblasts.ResultsTopo I in nuclear extracts of SSc fibroblasts generally showed a significantly lower efficiency than that of normal fibroblasts in relaxing equivalent amounts of supercoiled DNA. Increased sumoylation of topo I was clearly observed in 7 of 11 SSc fibroblast strains. Inhibition of SUMO1 with SUMO1 siRNA improved the catalytic efficiency of topo I in the SSc fibroblasts. In contrast, sumoylation of recombinant topo I proteins reduced their catalytic function.ConclusionsThe catalytic function of topo I was decreased in SSc fibroblasts, to which increased sumoylation of topo I may contribute.

[1]  Y. Mao,et al.  Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. Mouthon,et al.  New insights into the pathogenesis of systemic sclerosis. , 2003, Autoimmunity reviews.

[3]  Y. Mo,et al.  Nucleolar Delocalization of Human Topoisomerase I in Response to Topotecan Correlates with Sumoylation of the Protein* , 2002, The Journal of Biological Chemistry.

[4]  T. Mimori,et al.  Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. , 2000, Arthritis and rheumatism.

[5]  S. Shete,et al.  Extended Report , 2022 .

[6]  E. Beutner,et al.  Scl 70 antibody—a specific marker of systemic sclerosis , 1986, The British journal of dermatology.

[7]  Black,et al.  Systemic sclerosis: an autoantibody mosaic , 1999, Clinical and experimental immunology.

[8]  S. Shete,et al.  Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: Analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls (Annals of the Rheumatic Diseases (2010) 69, (822-827) DOI:10.1136/ard.2 , 2011 .

[9]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[10]  J. Smiley.  The many faces of scleroderma. , 1992, The American journal of the medical sciences.

[11]  G. Tsay,et al.  Autoantigen components recognizable by scleroderma sera are exported via ectocytosis of fibroblasts. , 1997, British journal of rheumatology.

[12]  Paul C. Gorski.  The Myth , 2022, Nkrumah and the Ghana Revolution.

[13]  M. Tremblay,et al.  Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. , 2004, Arthritis and rheumatism.

[14]  S. Morham,et al.  Targeted disruption of the mouse topoisomerase I gene by camptothecin selection , 1996, Molecular and cellular biology.

[15]  B. Giraudeau,et al.  Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? , 1999, Chest.

[16]  Morten O. Christensen,et al.  Distinct Effects of Topoisomerase I and RNA Polymerase I Inhibitors Suggest a Dual Mechanism of Nucleolar/Nucleoplasmic Partitioning of Topoisomerase I* , 2004, Journal of Biological Chemistry.

[17]  J. Seibold,et al.  Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin". , 2010, Arthritis and rheumatism.

[18]  J. Weinstein,et al.  Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. , 2007, Cancer research.

[19]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[20]  JAMES C. Wang,et al.  Cellular roles of DNA topoisomerases: a molecular perspective , 2002, Nature Reviews Molecular Cell Biology.

[21]  M. Xiong,et al.  HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans. , 2009, Arthritis and rheumatism.

[22]  P. Moitra,et al.  Sumoylation of Topoisomerase I Is Involved in Its Partitioning between Nucleoli and Nucleoplasm and Its Clearing from Nucleoli in Response to Camptothecin* , 2002, The Journal of Biological Chemistry.

[23]  M. Ellman,et al.  Topotecan and the development of scleroderma or a scleroderma-like illness. , 2002, Arthritis and rheumatism.

[24]  S. Jimenez,et al.  Topoisomerase I identified by scleroderma 70 antisera: enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Y. Pommier,et al.  RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. , 1996, Cancer research.

[26]  R. Hay,et al.  Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts , 2007, Proceedings of the National Academy of Sciences.

[27]  T. Hsieh,et al.  DNA topoisomerase I is essential in Drosophila melanogaster. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Ruzicka,et al.  Recruitment of topoisomerase I (Scl-70) to nucleoplasmic proteasomes in response to xenobiotics suggests a role for altered antigen processing in scleroderma. , 2005, Arthritis and rheumatism.

[29]  J. Reveille,et al.  Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. , 1996, Arthritis and rheumatism.

[30]  J. Champoux,et al.  Human DNA topoisomerase I: relaxation, roles, and damage control , 2005, Chromosoma.

[31]  J. She,et al.  SUMO wrestling with type 1 diabetes , 2005, Journal of Molecular Medicine.